Logo do repositório
 
Publicação

Effect of age and prior COVID-19 on BBIBP-CorV (Sinopharm) vaccination-induced antibody responses in a region with high seroprevalence

2022-06-21Preprint Acesso aberto
Ver registo simples
dc.contributor.authorHasan, Zahra
dc.contributor.authorMasood, Kiran Iqbal
dc.contributor.authorQaiser, Shama
dc.contributor.authorKhan, Erum
dc.contributor.authorHussain, Areeba
dc.contributor.authorGhous, Zara
dc.contributor.authorKhan, Unab
dc.contributor.authorHassan, Imran
dc.contributor.authorYameen, Maliha
dc.contributor.authorMemon, Haris Ali
dc.contributor.authorAli, Shiza
dc.contributor.authorBalouch, Sadaf
dc.contributor.authorNasir, Muhammad Imran
dc.contributor.authorQazi, Muhammad Farrukh
dc.contributor.authorVeldhoen, Marc
dc.contributor.authorSimas, J. Pedro
dc.contributor.authorBhutta, Zulfiqar A.
dc.contributor.authorMahmood, Syed Faisal
dc.contributor.authorHussain, Rabia
dc.contributor.authorGhias, Kulsoom
dc.date.accessioned2026-07-13T15:18:17Z
dc.date.available2026-07-13T15:18:17Z
dc.date.issued2022-06-21
dc.description.abstractIntroduction: Sinopharm (BBIBP-CorV) inactivated virus vaccination for COVID-19 has been administered widely in Pakistan. We investigated the dynamics of BBIBP-CorV -induced antibody responses over a 24 week period in a region with a high seroprevalence. Methods: Study subjects (n = 312) were followed up over a 24-week period between May and August 2021. Sera were tested for IgG antibodies to spike and the receptor binding domain (RBD). Results: Study subjects were 62% female. Twenty-two percent had a prior history of COVID-19. At 4-, 8- 16- and 24- weeks post-vaccination, the rate of IgG antibodies positive to spike was 57%, 87%, 66% and 90% of individuals, compared with to RBD which was 48%, 62%, 68% and 85% of subjects, respectively,. IgG to spike and RBD showed a positive correlation at each interval (rho > 0.6, p < 0.0001). Seropositivity to both spike and RBD was reduced in those aged 50 years and over for up until 16 weeks post-vaccination (p < 0.05). Individuals with prior COVID-19 infection showed greater antibody responses for up to 16 weeks post-vaccination (p < 0.05). SARS-CoV-2 infections were observed with a mean interval of 16 weeks postvaccination. Antibody responses did not wane for up to 6 months post-vaccination. Conclusions: Sinopharm vaccination-induced antibody responses were negatively impacted by age and positively impacted by prior COVID-19 for 16 weeks after vaccination. Importantly, we did not find waning of IgG antibodies to RBD over the study period. Maintenance of antibodies may be the result of continued community exposure and boosting with COVID-19 vaccination.eng
dc.identifier.doi10.21203/rs.3.rs-1763604/v1
dc.identifier.other191972f7-c7ac-47dd-ac19-a646fb7bdd8b
dc.identifier.urihttp://hdl.handle.net/10400.14/58694
dc.language.isoeng
dc.publisherResearch Square Platform LLC
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectBBIBP-CorV induced antibodieseng
dc.subjectIgGeng
dc.subjectRBDeng
dc.subjectSpikeeng
dc.subjectPrior COVID-19eng
dc.titleEffect of age and prior COVID-19 on BBIBP-CorV (Sinopharm) vaccination-induced antibody responses in a region with high seroprevalence
dc.typepreprint
dspace.entity.typePublication
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
155525506.pdf
Tamanho:
1.98 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

CBR - Working Papers / Preprints